431 related articles for article (PubMed ID: 16188393)
1. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
2. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.
Ahmed MH; Byrne CD
Diabetes Obes Metab; 2010 Nov; 12(11):958-66. PubMed ID: 20880342
[TBL] [Abstract][Full Text] [Related]
3. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
4. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
5. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Yamagishi S; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
[TBL] [Abstract][Full Text] [Related]
6. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia.
Miura S; Saku K
J Cardiol; 2008 Aug; 52(1):1-6. PubMed ID: 18639771
[TBL] [Abstract][Full Text] [Related]
8. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.
Davis HR; Veltri EP
J Atheroscler Thromb; 2007 Jun; 14(3):99-108. PubMed ID: 17587760
[TBL] [Abstract][Full Text] [Related]
9. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
11. Intestinal sterol transporters and cholesterol absorption inhibition.
Davis HR; Tershakovec AM; Tomassini JE; Musliner T
Curr Opin Lipidol; 2011 Dec; 22(6):467-78. PubMed ID: 22101558
[TBL] [Abstract][Full Text] [Related]
12. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe (Schering-Plough).
Meng CQ
Curr Opin Investig Drugs; 2001 Mar; 2(3):389-92. PubMed ID: 11575710
[TBL] [Abstract][Full Text] [Related]
14. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
15. [An inhibitor of intestinal cholesterol transporter].
Sano M
Nihon Rinsho; 2013 Sep; 71(9):1661-6. PubMed ID: 24205731
[TBL] [Abstract][Full Text] [Related]
16. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe: cholesterol lowering and beyond.
Bays HE; Neff D; Tomassini JE; Tershakovec AM
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):447-70. PubMed ID: 18402536
[TBL] [Abstract][Full Text] [Related]
18. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe prevents cholesterol gallstone formation in mice.
Zúñiga S; Molina H; Azocar L; Amigo L; Nervi F; Pimentel F; Jarufe N; Arrese M; Lammert F; Miquel JF
Liver Int; 2008 Aug; 28(7):935-47. PubMed ID: 18783541
[TBL] [Abstract][Full Text] [Related]
20. Ezetimibe in diabetes: more than cholesterol lowering?
Sarigianni M; Katsiki N; Mikhailidis DP
Curr Med Res Opin; 2010 Oct; 26(10):2517-20. PubMed ID: 20843163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]